KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Payables: 2009-2024

Historic Payables for Biomarin Pharmaceutical (BMRN) over the last 16 years, with Dec 2024 value amounting to $607.0 million.

  • Biomarin Pharmaceutical's Payables rose 11.57% to $798.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.7 billion, marking a year-over-year increase of 5.97%. This contributed to the annual value of $607.0 million for FY2024, which is 11.15% down from last year.
  • Latest data reveals that Biomarin Pharmaceutical reported Payables of $607.0 million as of FY2024, which was down 11.15% from $683.1 million recorded in FY2023.
  • In the past 5 years, Biomarin Pharmaceutical's Payables registered a high of $683.1 million during FY2023, and its lowest value of $492.5 million during FY2020.
  • Moreover, its 3-year median value for Payables was $607.0 million (2024), whereas its average is $621.0 million.
  • Its Payables has fluctuated over the past 5 years, first decreased by 13.68% in 2020, then climbed by 19.23% in 2023.
  • Biomarin Pharmaceutical's Payables (Yearly) stood at $492.5 million in 2020, then increased by 1.16% to $498.3 million in 2021, then grew by 14.99% to $573.0 million in 2022, then increased by 19.23% to $683.1 million in 2023, then declined by 11.15% to $607.0 million in 2024.